[en] Cytosine-phosphate-guanosine (CpG-ODN) has been described as a potent immunostimulatory agent in different species. No study reported the effect and safety of a P-class CpG when administered by systemic injection in healthy horses. The aim of this study was to evaluate the tolerance and the effect of an intramuscularly administered P-class CpG-ODN on hematology and on plasma cytokines (IFN-α,IL-10, TNF-α,IFN-γ) in eight healthy horses. Intra-muscular CpG-ODN or placebo (PBS) was administered twice at a 7 days-interval. Groups were inversed after 2 months of washout period. A physical examination, complete blood count (CBC) and plasma cytokine measurements were performed from 2 days before injection up to 21 days after injection.P-class CpG-ODN injection was well tolerated with minor side effects. After the first injection a significant transient drop in circulating total leukocytes, lymphocytes and an increase in monocytes were observed. A transient drop in circulating eosinophils was also noted during 48 hours after each CpG injection. P-class CpG-ODN at a dose of 5 mg can be safely used in horses. A redistribution of white blood cells was observed in horses receiving CpG, but no change in plasma cytokines was observed at the indicated dose, route of administration and sampling times.
Disciplines :
Veterinary medicine & animal health Anatomy (cytology, histology, embryology...) & physiology
Author, co-author :
Tosi, Irène ; Université de Liège - ULiège > Département des sciences fonctionnelles (DSF) > Phys. neuro-muscul., de l'effort - Méd. sport. des animaux
Frellstedt, Linda; Institute of Veterinary, Animal and Biomedical Sciences, Massey University, 17 Tennent Drive, Palmerston North 4442, New Zealand
Bureau, Fabrice ; Université de Liège - ULiège > Département des sciences fonctionnelles (DSF) > GIGA-R : Biochimie et biologie moléculaire
Farnir, Frédéric ; Université de Liège - ULiège > Dpt. de gestion vétérinaire des Ressources Animales (DRA) > Biostatistiques et bioinformatique appliquées aux sc. vétér.
Denoix, J.M.; CIRALE, National Veterinary School of Maisons-Alfort, R.D. 675, 14430, Goustranville, France
Lekeux, Pierre ; Université de Liège - ULiège > Département des sciences fonctionnelles (DSF) > Physiologie
Art, Tatiana ; Université de Liège - ULiège > Département des sciences fonctionnelles (DSF) > Phys. neuro-muscul., de l'effort - Méd. sport. des animaux
Language :
English
Title :
Effects of a P-class CpG-ODN administered by intramuscular injection on plasma cytokines and on white blood cells of healthy horses
Ajana, F., Sana, C., Caulin, E., Are there differences in immunogenicity and safety of vaccines according to the injection method?. Med. Mal. Infect. 38:12 (2008), 648–657.
Banerjee, B., Kelly, K.J., Fink, J.N., Modulation of airway inflammation by immunostimulatory CpG oligodeoxynucleotides in a murine model of allergic aspergillosis. Infect. Immun. 72:10 (2004), 6087–6094.
Behrens, N.E., Gershwin, L.J., Immune modulation of T regulatory cells and IgE responses in horses vaccinated with West Nile virus vaccine combined with a CpG ODN. Vaccine 33 (2015), 5764–5771.
Bode, C., Zhao, G., Steinhagen, F., Kinjo, T., Klinman, D.M., CpG DNA as a vaccine adjuvant. Expert. Rev. Vaccines 10:4 (2011), 499–511.
Bohle, B., CpG motifs as possible adjuvants for the treatment of allergic diseases. Int. Arch. Allergy. Immunol. 129:3 (2002), 198–203.
Cooper, C.L., Davis, H.L., Morris, M.L., Efler, S.M., Adhami, M.A., Krieg, A.M., Cameron, D.W., Heathcote, J., CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study. J. Clin. Immunol. 24:6 (2004), 693–701.
Deng, G.M., Liu, Z.Q., Tarkowski, A., Intracisternally localized bacterial DNA containing CpG motifs induces meningitis. J. Immunol. 167 (2001), 4616–4626.
Elkins, K.L., Rhinehart-Jones, T.R., Stibitz, S., Conover, J.S., Klinman, D.M., Bacterial DNA containing CpG motifs stimulates lymphocyte-dependent protection of mice against lethal infection with intracellular bacteria. J. Immunol. 162 (1999), 2291–2298.
Hayashi, T., Hasegawa, K., Sasaki, Y., Systemic Administration of olygodeoxynucleotides with CpG motifs at priming phase reduces local Th2 response and late allergic rhinitis in BALB/c mice. Inflammation 31:1 (2007), 47–56.
Heikenwalder, M., Polymenidou, M., Junt, T., Sigurdson, C., Wagner, H., Akira, S., Zinkernagel, R., Aguzzi, A., Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration. Nat. Med. 10:2 (2004), 187–192.
Hoebe, K., Janssen, E., Beutler, B., The interface between innate and adaptive immunity. Nat. Immunol. 5:10 (2004), 971–974.
Hornung, V., Rothenfusser, S., Britsch, S., Krug, A., Jahrsdörfer, B., Giese, T., Endres, S., Hartmann, G., Quantitative expression of Toll-Like receptor 1–10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J. Immunol. 168 (2002), 4531–4537.
Ioannou, X.P., Griebel, P., Mena, A., Gomis, S.L., Godson, D.L., Mutwiri, G., Hecker, R., Babiuk, L.A., Van Drunen Littel-Van Den Hurk, S., Safety of CpG oligodeoxynucleotides in veterinary species. Antisense Nucleic Acid. Drug. Dev. 13:3 (2003), 157–167.
Iwasaki, A., Medzhitov, R., Toll-like receptor control of the adaptive immune responses. Nat. Immunol. 5:10 (2004), 987–995.
Klier, J., May, A., Fuchs, S., Schillinger, U., Plank, C., Winter, G., Gehlen, H., Coester, C., Immunostimulation of bronchoalveolar lavage cells from recurrent airway obstruction-affected horses by different CpG-classes bound to gelatin nanoparticles. Vet. Immunol. Immunopathol. 144 (2011), 79–87.
Klier, J., Fuchs, S., May, A., Schillinger, U., Plank, C., Winter, G., Gehlen, H., Coester, C., A nebulized gelatin nanoparticle-based cpg formulation is effective in immunotherapy of allergic horses. Pharm. Res. 29 (2012), 1650–1657.
Klier, J., Lehmann, B., Fuchs, S., Reese, S., Hirschmann, A., Coester, C., Winter, G., Gehlen, H., Nanoparticulate CpG immunotherapy in RAO-affected horses: phase I and IIa study. J. Vet. Internal Med. 29 (2015), 286–293.
Klier, J., Geis, S., Steuer, J., Reese, S., Fuchs, S., Mueller, R.S., Winter, G., Gehlen, H., Comparison of nanoparticulate CpG immunotherapy with and without allergens in RAO-affected horses. Br. Equine Vet. Assoc. Congr., 47(Suppl. 48), 2015.
Kline, J.N., Kitagaki, K., Businga, T.R., Jain, V.V., Treatment of established asthma in a murine model using CpG oligodeoxynucleotides. Am. J. Physiol. Lung Cell. Mol. Physiol. 283 (2002), L170–L179.
Krieg, A.M., Efler, S.M., Wittpoth, M., Al Adhami, M.J., Davis, H.L., Induction of systemic TH1-Like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-Class CpG oligodeoxynucleotide TLR9 Agonist. J. Immunother. 27:6 (2004), 460–471.
Krieg, A.M., Therapeutic potential of Toll-like receptor 9 activation. Nat. Rev. Drug Discov., 5(6), 2006 471–448.
Li, H.T., Zhang, T.T., Chen, Z.G., Ye, J., Liu, H., Zou, X.L., Wang, Y.H., Yang, H.L., Intranasal administration of CpG oligodeoxynucleotides reduces lower airway inflammation in a murine model of combined allergic rhinitis and asthma syndrome. Int. Immunopharmacol. 28:1 (2015), 390–398.
Lopez, A.M., Hecker, R., Mutwiri, G., van Drunen Littel-van den Hurk, S., Babiuk, L.A., Townsend, H.G.G., Formulation with CpG ODN enhances antibody responses to an equine influenza virus vaccine?. Vet. Immunol. Immunopathol. 114:1–2 (2006), 103–110.
Lund, J.M., Alexopoulou, L., Sato, A., Karow, M., Niels, C., Adams, N.C., Gale, W., Iwasaki, A., Flavell, R.A., Recognition of single-stranded RNA viruses by Toll-like receptor 7. PNAS 101:15 (2004), 5598–5603.
Mutwiri, G., Pontarollo, R., Babiuk, S., Griebel, P., van Drunene Little-van den Hurk, S., Mena, A., Tsang, C., Alcon, V., Nichani, A., Ioannou, X., Gomis, S., Townsend, H., Heckers, R., Potter, A., Babiuk, L.A., Biological activity of immunostimulatory CpG DNA motifs in domestic animals. Vet. Immunol. Immunopathol. 91:2 (2003), 89–103.
Mutwiri, G.K., Nichani, A.K., Babiuk, S., Babiuk, L.A., Strategies for enhancing the immunostimulatory effects of CpG oligodeoxynucleotides. J. Control. Release 97:1 (2004), 1–17.
Nichani, A.K., Mena, A., Popowych, Y., Denta, D., Townsenda, H.G.G., Mutwiria, G.K., Heckerb, R., Babiuka, L.A., Griebela, P.J., In vivo immunostimulatory effects of CpG oligodeoxynucleotide in cattle and sheep?. Vet. Immunol. Immunopathol. 98:1–2 (2004), 17–29.
Ross, J., Smith, N.P., White, I.R., Role of aluminium sensitivity in delayed persistent immunisation reactions. J. Clin. Pathol. 44 (1991), 876–878.
Samulowitz, U., Weber, M., Weeratna, R., Uhlmann, E., Noll, B., Krieg, A.M., Vollmer, J., A novel class of immune-stimulatory CpG oligodeoxynucleotides unifies high potency in type I interferon induction with preferred structural properties. Oligonucleotides 20:2 (2010), 93–101.
Scheiermann, J., Klinman, D.M., Clinical evaluation of CpG oligonucleotides as adjuvants for vaccines Targeting infectious diseases and cancer. Vaccine 32:48 (2014), 6377–6389.
Shirota, H., Klinman, D.M., Recent progress concerning CpG DNA and its use as a vaccine adjuvant. Expert. Rev. Vaccines 13:2 (2014), 299–312.
Simons, F.E.R., Shikishima, Y., Van Nest, G., Eiden, J.J., HayGlass, K.T., Selective immune redirection in humans with ragweed allergy by injecting Amb a 1 linked to immunostimulatory DNA. J. Allergy Clin. Immun. 113:6 (2004), 1144–1151.
Van der Stede, Y., Verdonck, F., Vancaeneghem, S., Cox, E., Goddeeris, B.M., CpG-oligodinucleotides as an effective adjuvant in pigs for intramuscular immunizations. Vet. Immunol. Immunopathol. 86 (2002), 31–41.
Vicari, A.P., Schmalbach, T., Lekstrom-Himes, J., Morris, M.L., Al-Adhami, M.J., Laframboise, C., Leese, P., Krieg, A.M., Efler, S.M., Davis, H.L., Safety, pharmacokinetics and immune effects in normal volunteers of CPG 10101 (ACTILON), an investigational synthetic toll-like receptor 9 agonist. Antiviral Ther. 12:5 (2007), 741–751.
Vogel, F.R., Powell, M.F., A compendium of vaccine adjuvants and excipients. Pharm. Biotechnol. 6 (1995), 141–228.
Vollmer, J., Krieg, A.M., Immunotherapeutic applications of CpG olygodeoxynucleotide TLR9 agonists. Adv. Drug Deliv. Rev. 61:3 (2009), 195–204.
Weeratna, R.D., Brazolot Millan, C.L., McCluskie, M.J., Davis, H.L., CpG ODN can re-direct the Th bias of established Th2 immune responses in adult and young mice. FEMS Immunol. Med. Microbiol. 32:1 (2001), 65–71.
Wingender, G., Garbi, N., Schumak, B., Jüngerkes, F., Endl, E., von Bubnoff, D., Steitz, J., Striegler, J., Moldenhauer, G., Tüting, T., Heit, A., Huster, K.M., Takikawa, O., Akira, S., Busch, D., Wagner, H., Hämmerling, G.J., Knolle, P.A., Limmer, A., Systemic application of CpG-rich DNA suppresses adaptive T cell immunity via induction of IDO. Eur. J. Immunol. 36:1 (2006), 12–20.
